BriaCell Therapeutics (TSE:BCT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BriaCell Therapeutics has reported significant advancements in treating advanced metastatic breast cancer with its novel immunotherapy, Bria-IMT™, evidenced by a doubling in median progression-free survival to 4.1 months for ADC-resistant patients and an 83% intracranial objective response rate at the ASCO 2024 Annual Meeting. The Phase 2 study results show a 55% clinical benefit rate across various patient groups, suggesting a potential game-changing therapy for those with limited treatment options.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.